The emerging paradigm demands an integrative approach, where biology, technology, and clinical applications intersect seamlessly. To facilitate this integration, the new journal Advanced Cancer Research has been established as an international, peer-reviewed platform dedicated to publishing high-caliber research encompassing basic science, translational studies, and clinical trials. The journal’s mission is to prioritize contributions that not only delve into the mechanistic underpinnings of cancer but also drive conceptual innovation and technological breakthroughs. With a sharp focus on research that traverses disciplinary boundaries, it aims to catalyze advances that directly inform therapeutic development.

The scientific scope of Advanced Cancer Research reflects the convergent and interdisciplinary nature of modern oncology. It invites submissions across a broad spectrum of fields—from cancer molecular biology and genomics to the tumor microenvironment and metastasis. Particularly emphasized are studies exploring cancer heterogeneity and stem cell plasticity, which are pivotal in understanding tumor evolution and therapeutic resistance. The journal also highlights emergent domains such as the interplay between cancer and the microbiome, aging biology, synthetic and structural biology, and the incorporation of artificial intelligence and machine learning to decode complex oncogenic pathways.

Innovative experimental models receive particular attention, including the development and application of organoids, organ-on-chip systems, and advanced three-dimensional tumor models. These cutting-edge platforms recapitulate the tumor microenvironment more accurately than traditional two-dimensional cultures, bridging the gap between in vitro studies and in vivo physiology. Moreover, multi-omics approaches integrating genomics, transcriptomics, proteomics, and metabolomics data open new avenues for systemic insight, enabling the identification of novel biomarkers and therapeutic targets.

One of the cardinal tenets underpinning the journal’s philosophy is the recognition that cancer research cannot be siloed. Rather than compartmentalizing molecular discoveries, experimental models, or clinical observations as isolated entities, Advanced Cancer Research aspires to forge synergies that connect these dimensions. This integrative outlook is crucial for translating complex biological phenomena into effective treatment strategies that address cancer’s inherent heterogeneity and adaptive capabilities.

The editorial process at Advanced Cancer Research reflects a commitment to rigor, transparency, and inclusivity. Employing a stringent peer review system, the journal assesses each submission based on scientific merit, originality, and potential impact. Methodological precision, ethical compliance, and reproducibility are core criteria, ensuring published works stand up to the highest standards of scientific integrity. Open access publishing enhances the reach and impact of research findings, facilitating unrestricted dissemination to researchers, clinicians, and stakeholders worldwide.

As cancer is a global challenge, the journal draws on a diverse editorial board composed of leading researchers and clinicians from across continents, including representation from the United States, United Kingdom, China, South Korea, Japan, and Singapore. This diverse panel ensures comprehensive expertise and a broad perspective that reflects the international nature of oncology research today. The global approach strengthens the platform’s ability to address regional variations in cancer biology and treatment paradigms.

Supporting the next generation of cancer scientists is a cornerstone of the journal’s vision. Recognizing that innovation often springs from early-career investigators, Advanced Cancer Research actively encourages submissions from emerging researchers who bring fresh outlooks and novel methodologies. Through constructive and developmental peer review, the journal fosters a nurturing environment where promising work can reach its full potential, contributing to the evolving landscape of oncology.

In addition to foundational biology, the journal champions research at the intersection of cancer science and the latest technological developments. The integration of artificial intelligence and machine learning offers unprecedented opportunities to analyze vast datasets, uncover hidden patterns, and accelerate hypothesis generation. Similarly, advances in nanomedicine open new frontiers in targeted drug delivery and diagnostic precision. These intersecting technologies hold the promise to revolutionize cancer treatment by personalizing therapy at an individual patient level.

The tumor microenvironment, including the immune landscape, is a critical focus of translational research featured within the journal. Immunotherapy, now a staple in cancer treatment, continues to evolve, with new modalities aiming to overcome resistance and enhance efficacy. Understanding how metabolic reprogramming, epigenetic modifications, and cell-cell interactions within the microenvironment drive cancer progression is key to developing these next-generation therapies. Likewise, the role of senescence and aging in cancer incidence and response to therapy are topical themes expanding the conceptual framework.

Liquid biopsy technologies, offering minimally invasive means to monitor tumor dynamics via blood or other bodily fluids, exemplify the translational innovations the journal seeks to highlight. These tools facilitate real-time tracking of tumor evolution, treatment response, and resistance mechanisms, potentially transforming clinical decision-making. Coupled with sophisticated computational analysis, the integration of liquid biopsy data into patient management represents a leap toward precision oncology.

In sum, Advanced Cancer Research positions itself as a vital crucible where integrative and forward-looking cancer research can unfold. The journal aspires to be a nexus for critical appraisal, open discourse, and collaborative innovation, channeling the synergy of diverse scientific domains to accelerate the translation of knowledge into tangible patient benefits. As oncology continues its rapid evolution, this platform offers an indispensable venue for shaping the future trajectory of cancer research and therapy.

Subject of Research: Not applicable
Article Title: Advanced Cancer Research: defining a platform for convergent oncology
News Publication Date: 28-Jan-2026
Web References: http://dx.doi.org/10.55092/acr20260001
References: Dong Z. Advanced Cancer Research: defining a platform for convergent oncology. Adv. Cancer Res. 2026(1):0001
Keywords: Cancer, molecular biology, genomics, immunotherapy, tumor microenvironment, cancer heterogeneity, stem cell plasticity, artificial intelligence, machine learning, liquid biopsy, organoids, nanomedicine

TOPK, a serine/threonine kinase initially identified in activated T lymphocytes, has gained increasing attention for its oncogenic functions across a wide spectrum of malignancies. However, its specific contribution to kidney cancer pathogenesis has remained elusive until now. This study bridges that gap by demonstrating a marked overexpression of TOPK in KIRC tissues compared to normal kidney counterparts. Intriguingly, this overexpression correlates with altered promoter methylation patterns, suggesting an epigenetic mechanism regulating TOPK expression that may be exploited for therapeutic intervention.

One of the most striking findings of the study is the independent prognostic value of TOPK expression in KIRC patients. Utilizing large-scale patient cohorts and robust statistical modeling, high TOPK levels emerged as a predictor of poor overall survival, emphasizing its clinical relevance. Unlike traditional biomarkers that often fail to capture the dynamic tumor-host interplay, TOPK reflects a molecular nexus influencing not only tumor cell behavior but also the immune landscape, a feature critical for precision oncology.

Delving deeper into the tumor immunology context, the investigators employed state-of-the-art computational tools to dissect immune cell infiltration patterns in KIRC tumors with varying levels of TOPK expression. High TOPK expression was associated with a conspicuous depletion of cytotoxic immune effectors such as CD8+ T cells and natural killer (NK) cells. Concomitantly, these tumors exhibited elevated expression of immune checkpoint molecules, including PD-L1 and CTLA-4, which are known to dampen anti-tumor immunity. This dual effect suggests that TOPK actively contributes to establishing an immunosuppressive microenvironment that enables tumor cells to evade immune surveillance.

To unravel the signaling cascades downstream of TOPK, the researchers performed functional enrichment and pathway analyses, revealing its association with key inflammatory and oncogenic pathways. Notably, TOPK interlinks with NOTCH1 signaling, a pathway implicated in vascular remodeling and tumor growth; TNF-α, a pleiotropic cytokine that shapes inflammatory responses; and TGF-β signaling, recognized for its immunosuppressive and pro-fibrotic roles within tumors. This multifaceted involvement highlights TOPK as a central orchestrator of tumor-promoting inflammation and immune escape mechanisms.

In an innovative translational approach, the research team harnessed in vivo tumor models deficient in TOPK expression to validate its role under physiological immune conditions. Although the primary models were non-renal in origin, the immunocompetent mouse systems provided compelling evidence that loss of TOPK alters tumor-associated inflammatory profiles. Specifically, TOPK-deficient tumors exhibited changes consistent with diminished immunosuppression, offering a rationale for therapeutic targeting of TOPK to reinvigorate anti-tumor immunity.

The capacity of TOPK to modulate immune checkpoints and cytotoxic lymphocyte infiltration positions it as a prime candidate for combination therapies integrating kinase inhibitors with immune checkpoint blockade. This is particularly significant given the current clinical challenges in treating KIRC, where durable responses to immunotherapy remain limited. Inhibiting TOPK activity could potentially sensitize tumors to immune-mediated destruction, overcoming resistance and improving patient outcomes.

Mechanistically, the epigenetic regulation of TOPK via promoter methylation adds another layer of complexity and therapeutic opportunity. Targeting the epigenome to modulate TOPK expression may synergize with direct kinase inhibition, providing a dual assault on tumor progression and immune evasion. Furthermore, the accessibility of TOPK as a kinase makes it amenable to small molecule drug development, accelerating the path toward clinical translation.

This multidisciplinary study not only highlights the prognostic significance of TOPK but also illuminates its instrumental role in reshaping the tumor microenvironment. By fostering an immunosuppressive milieu, TOPK facilitates tumor growth and metastasis, underscoring its potential as a molecular choke point in KIRC pathology. The use of comprehensive bioinformatics alongside experimental validation sets a new standard for uncovering clinically relevant molecular targets in complex cancers.

The implications extend beyond KIRC as well, given the pervasive role of TOPK in other malignancies. Insights into its immunomodulatory functions could spur broader therapeutic innovations across oncology. Moreover, elucidation of TOPK’s interactions with pivotal signaling pathways offers fertile ground for combination regimens aimed at multiple tumor-promoting axes simultaneously.

Future studies are warranted to develop selective TOPK inhibitors and assess their clinical efficacy both as monotherapy and in combination with existing immunotherapies such as PD-1/PD-L1 antibodies. Additionally, unraveling the precise molecular mechanisms through which TOPK interfaces with immune checkpoint regulation and inflammatory signaling will provide deeper insights into tumor immunobiology.

In conclusion, this study propounds TOPK as a novel prognostic biomarker and an actionable immunotherapeutic target in kidney renal clear cell carcinoma. Its dual role in driving tumor progression and subverting immune responses encapsulates the complexity of tumor biology that modern oncology strives to overcome. Targeting TOPK could herald a new era of more effective, personalized therapies tailored to dismantle the immunosuppressive barriers that guard KIRC tumors, ultimately improving patient survival and quality of life.

Subject of Research: The role of TOPK in immune suppression and prognosis in kidney renal clear cell carcinoma (KIRC).

Article Title: TOPK promotes immune suppression in kidney renal clear cell carcinoma and emerges as a prognostic and therapeutic target.

Article References:
Zheng, Z., Xiong, R., Sui, X. et al. TOPK promotes immune suppression in kidney renal clear cell carcinoma and emerges as a prognostic and therapeutic target. BMC Cancer 25, 1334 (2025). https://doi.org/10.1186/s12885-025-14665-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14665-0